New radiopharmaceutical shows antitumor activity in patients with advanced prostate cancer
Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy ...
Tag: Radiopharmaceutical
Newly developed PSG score improves patient selection for PSMA radiopharmaceutical therapy
Reston, VA—A newly established PSMA PET scoring system can successfully predict whether metastatic castration-resistant prostate cancer (mCRPC) patients will respond ...
Blood-based biomarkers accurately predict neuroendocrine tumor response to radiopharmaceutical therapy
Reston, VA—A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) ...
Markey Cancer Center study shows potential for new radiopharmaceutical cancer treatment
LEXINGTON, Ky. (Feb. 24, 2023) — A recent University of Kentucky Markey Cancer Center study suggests a new radiopharmaceutical compound may be a ...
Targeting refractory prostate cancer: a novel radiopharmaceutical hits the bull’s-eye
Osaka, Japan - As the saying goes, when all you have is a hammer, everything looks like a nail; and ...
Novel radiopharmaceutical pair detects and treats melanoma; study shows potential for broad application in solid tumors
Vancouver, British Columbia, Canada — A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study, according ...
SNMMI designates first Radiopharmaceutical Therapy Centers of Excellence
Reston, VA—The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has named Stanford Health Care and the Dana-Farber Brigham Cancer ...